THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has invited the Company to participate at an upcoming meeting of the Oncologic Drugs Advisory Committee (ODAC). The Company’s understanding is that the ODAC will review progress made by Amgen and other sponsors in delineating the effects of erythropoiesis-stimulating agents (ESAs) on survival and tumor progression in cancer patients. The ODAC meeting is scheduled for May 10, 2007.
